Vestibo tablets 16mg, no. 30

Dropsy of the labyrinth of the inner ear;

Vestibular and labyrinthine disorders: dizziness, noise and ear pain, headache, nausea, vomiting, hearing loss; vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations),

Meniere's disease.

As part of complex therapy:

vertebrobasilar insufficiency;

post-traumatic encephalopathy;

cerebral atherosclerosis.

Inside, during meals, without chewing, with a small amount of liquid.

Tablets with a dosage of 8 and 16 mg: 8-16 mg 2-4 times a day. The treatment is long-term.

Tablets with a dosage of 24 mg: 1 / 2-1 table. 2 times a day. The maximum daily dose is 48 mg.

Active ingredient: betahistine dihydrochloride - 16 mg;

Excipients:

povidone K90;

MCC;

lactose monohydrate;

colloidal silicon dioxide;

crospovidone;

thearic acid;

purified water (not contained in the finished product)

Hypersensitivity;

Pheochromocytoma;

Bronchial asthma;

Peptic ulcer and duodenal ulcer in the acute phase;

Pregnancy (I trimester).

Carefully:

peptic ulcer or duodenal ulcer (history);

pregnancy (II Ц III trimester);

childhood.

pharmachologic effect

Synthetic analogue of histamine. It is a weak agonist of histamine H1 receptors and a rather potent antagonist of histamine H3 receptors. It has a histamine-like and vasodilating effect. Affects the cochlear blood flow and the central vestibular apparatus. The action of the drug includes vasodilation in the inner ear (indirectly through histamine H3 and H1 receptors), an inhibitory effect on the vestibular nuclei (through histamine H3 receptors) and impulse activity of ampullar receptors. By directly agonizing the histamine H1 receptors of the inner ear vessels and the precapillary sphincters of the microvasculature located in the stria vascularis, as well as indirectly through the histamine H3 receptors, it improves microcirculation and capillary permeability of the inner ear,normalizes endolymph pressure in the labyrinth and cochlea, increases blood flow in the basilar artery. It has a pronounced central effect, being an antagonist of histamine H3 receptors of the vestibular nerve nuclei. Normalizes the conductivity in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.increases blood flow in the basilar artery. It has a pronounced central effect, being an antagonist of the histamine H3 receptors of the vestibular nerve nuclei. Normalizes the conductivity in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.increases blood flow in the basilar artery. It has a pronounced central effect, being an antagonist of histamine H3 receptors of the vestibular nerve nuclei. Normalizes the conductivity in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.being an antagonist of histamine H3 receptors of the vestibular nerve nuclei. Normalizes the conductivity in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.being an antagonist of histamine H3 receptors of the vestibular nerve nuclei. Normalizes the conductivity in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.By indirectly acting on histamine H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.Betahistine stimulates histamine H1 receptors, therefore it does not have a sedative effect and does not cause drowsiness.

Pharmacokinetics

Absorption and distribution

After oral administration, betahistine dihydrochloride is rapidly absorbed. Cmax in plasma is reached after 3 hours.

Plasma protein binding is low. Withdrawal T1 / 2 is 3-4 hours.

It is almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours.

Side effect

From the digestive system: dyspepsia (nausea, vomiting). Allergic reactions: skin rash, Quincke's edema.

Application during pregnancy and lactation

The drug is contraindicated for use in the first trimester of pregnancy.

Carefully

the drug should be prescribed in the II and III trimesters of pregnancy.

Application in children

The drug should be prescribed with caution to children.

special instructions

In some cases, the therapeutic effect of the drug appears only a few months after the start of treatment.

Overdose

Symptoms: headache, facial flushing, dizziness, tachycardia, decreased blood pressure, bronchospasm.

Drug interactions

Antihistamines, when taken simultaneously, reduce the effect of Vestibo.